



DEPARTMENT OF HEALTH & HUMAN SERVICES

PUBLIC HEALTH SERVICE
NATIONAL INSTITUTES OF HEALTH

FOR US POSTAL SERVICE DELIVERY:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500, MSC 6910
Bethesda, Maryland 20892-6910
Home Page: <http://grants.nih.gov/grants/olaw/olaw.htm>

FOR EXPRESS MAIL:

Office of Laboratory Animal Welfare
6700B Rockledge Drive, Suite 2500
Bethesda, Maryland 20817
Telephone: (301) 496-7163
Facsimile: (301) 480-3387

October 5, 2021

Re: Animal Welfare Assurance
A3347-01 [OLAW Case 3F]

Dr. Emmanuel Giannelis,
Vice Provost for Life Sciences
Cornell University
(b) (4) Day Hall
Ithaca, NY 14850

Dear Dr. Giannelis,

The Office of Laboratory Animal Welfare (OLAW) acknowledges receipt of your September 29, 2021 letter reporting an instance of noncompliance with the PHS Policy on Humane Care and Use of Laboratory Animals at Cornell University. According to the information provided, OLAW understands that on August 2, 2021, a 36-day-old C57Bl/6 mouse died shortly after an intraperitoneal (IP) injection of sterile corn oil. The animal was in a cohort of nine 36 to 38-day-old mice that were receiving their first daily IP injection of tamoxifen or vehicle (corn oil). Average BW of the cohort was 14.6 ± 0.8 g, and the focal mouse was the largest of the group at 16.0 g. Examination of the focal mouse's abdominal cavity showed blood surrounding abdominal organs. The remaining eight animals showed no adverse signs following their IP injections. The affected animal was on an activity that was funded by the NSF (IOS-2005919).

Corrective and preventive actions: based on these findings, the postdoc who had performed the procedure has undergone retraining for IP injections with the training coordinators at the Center for Animal Resources and Education.

The prompt consideration of this matter by Cornell University was consistent with the philosophy of institutional self-regulation. Similarly, the actions taken to resolve the issue and prevent recurrence were appropriate. We appreciate being informed of this matter and find no cause for further action by this office.

Sincerely,

Brent C. Morse -S

Digitally signed by Brent C.
Morse -S
Date: 2021.10.06 09:29:18 -04'00'

Brent C. Morse, DVM

Director

Division of Compliance Oversight

Office of Laboratory Animal Welfare

cc: IACUC contact
NSF Animal Welfare Officer



Cornell University
Office of
Research Integrity and Assurance

395 Pine Tree Road, Suite 320
 Ithaca, NY 14850
 Phone: 607-255-2214
 Fax: 607-255-0758
 Email: iacuc@cornell.edu
www.oria.cornell.edu

September 29, 2021

Axel Wolff, MS, DVM, DACLAM
 Deputy Director, Office of Laboratory Animal Welfare
 National Institutes of Health
 6700B Rockledge Drive, Suite 2500, MSC 6910
 Bethesda, MD 20892

Animal Welfare Assurance Number: D16-00225 (A3347-01) Cornell University – Ithaca
 PHS Grant or Contract Number: NSF IOS-2005919

Dear Dr. Wolff:

As Institutional Official for Cornell University's animal care and use program, I am reporting an adverse event that occurred under our General Assurance. This incident involving one mouse occurred on August 2, 2021 and was reported to the IACUC at the September 16, 2021 meeting. The IACUC agreed that the corrective actions taken were appropriate.

Explanation of the situation:

A 36-day-old C57Bl/6 mouse died shortly after an intraperitoneal (IP) injection of sterile corn oil. The animal was in a cohort of nine 36 to 38-day-old mice that were receiving their 1st daily IP injection of tamoxifen or vehicle (corn oil). Average BW of the cohort was 14.6 ± 0.8 g, and the focal mouse was the largest of the group at 16.0 g. The remaining eight animals showed no adverse signs following their IP injections.

Action taken by the institution:

Examination of the focal mouse's abdominal cavity showed blood surrounding abdominal organs. Based on these findings, the postdoc who had performed the procedure has undergone retraining for IP injections with the training coordinators at the Center for Animal Resources and Education.

If you have any questions concerning this adverse event that occurred under our General Assurance, please contact Christine Bellezza, Director of Research Assurance in the Office of Research Integrity and Assurance at cab37@cornell.edu.

Sincerely,

(b) (6)

Emmanuel Giannelis
 Vice President for Research and Innovation

cc:

(b) (6)

C. Bellezza
 AAALAC International

Wolff, Axel (NIH/OD) [E]

From: OLAW Division of Compliance Oversight (NIH/OD)
Sent: Friday, October 1, 2021 7:21 AM
To: Christine A. Bellezza
Cc: OLAW Division of Compliance Oversight (NIH/OD)
Subject: RE: Cornell University Report of Noncompliance

Thank you for this report, Dr. Bellezza. We will send a response soon.
Axel Wolff

From: Christine A. Bellezza <cab37@cornell.edu>
Sent: Wednesday, September 29, 2021 2:27 PM
To: OLAW Division of Compliance Oversight (NIH/OD) <olawdco@od.nih.gov>
Cc: (b) (6) Office of the Vice President for Research and Innovation <vp_research@cornell.edu>; gborkowski@aaalac.org; (b) (6)
Subject: Cornell University Report of Noncompliance

Dear Dr. Wolff,

Please see the attached report from Cornell University's Vice President for Research and Innovation, Dr. Emmanuel Giannelis, describing an adverse event that occurred under our General Assurance. Please let me know if you have any questions or concerns.

Sincerely,
Chris

Christine A. Bellezza, DVM
Director of Research Assurance
Office of Research Integrity and Assurance (ORIA)
Cornell University / (b) (4) 395 Pine Tree Rd / Ithaca, NY 14850
T (b) (6) / Email cab37@cornell.edu
www.oria.cornell.edu